“Dangling” Accelerated Approvals in Oncology

In 1992, an accelerated approval pathway for pharmaceutical products was added to the Code of Federal Regulations in an attempt to address unmet medical needs of patients with serious or life-threatening diseases. The pathway allows the Food and Drug Administration (FDA) to approve a drug on the…

Lascia un commento